Cephalon’s Nuvigil For Jet Lag Is Pulled Off The Runway; Bipolar Indication Remains On The Horizon
This article was originally published in The Pink Sheet Daily
Executive Summary
A second “complete response” letter from FDA derails development of the jet lag claim; Cephalon repeatedly has struck out in seeking a new indication to differentiate the wakefulness drug from Provigil.
You may also be interested in...
Strong Year For Cephalon, But An Uncertain Future Remains
The specialty pharma has made plenty of acquisitions and is pursuing late-stage options, but the upcoming loss of its lead product to generic competition may not be filled by the risky pipeline.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.